news
Study shows no benefit of convalescent plasma for COVID-19 patients
An NIH trial found that COVID-19 convalescent plasma did not prevent disease progression in high-risk outpatients with early symptoms.
List view / Grid view
Convalescent plasma (CP) therapy
article
Plasma-derived therapies require a mastery of advanced bioproduction techniques
Plasma-derived therapies and medicines provide life-changing treatments for patients around the world who suffer from serious, and often rare, diseases that affect the immune system or result from non-functioning proteins in blood plasma. Carole Resman, Executive Vice President Production at LFB, describes the complex and highly regulated manufacturing process of…
news
NIH halts COVID-19 convalescent plasma trial
The trial evaluating COVID-19 convalescent plasma as a treatment for COVID-19 patients with mild to moderate symptoms was stopped due to ineffectiveness.
news
US expands COVID-19 convalescent plasma treatment trials
Operation Warp Speed and the NIH are funding the expansion of two trials evaluating the efficacy of convalescent plasma therapy in hospitalised COVID-19 patients.
news
FDA issues emergency use authorisation for COVID-19 convalescent plasma
The emergency use authorisation (EUA) allows the distribution and administration of COVID-19 convalescent plasma to hospitalised patients in the US.
news
COVID-19 convalescent plasma therapy shown to be safe and effective
Scientists reveal 76 percent of critically ill trial participants treated with convalescent plasma are recovering, with almost half now discharged from hospital.
news
COVID-19 convalescent plasma therapy shows promise in pilot study
A pilot trial of convalescent plasma therapy in 10 severe COVID-19 patients has shown it may be a safe and promising therapeutic option.
